Neurotrophic factors for the treatment of Parkinson's disease

Show simple item record

dc.contributor.author Sullivan, Aideen M.
dc.contributor.author Toulouse, André
dc.date.accessioned 2012-11-12T13:41:45Z
dc.date.available 2012-11-12T13:41:45Z
dc.date.copyright 2011
dc.date.issued 2011-06
dc.identifier.citation Sullivan A.M., Toulouse A.; (2011) 'Neurotrophic factors for the treatment of Parkinson's disease'. Cytokine & Growth Factor Reviews, 22 (3):157-165. doi: http://dx.doi.org/10.1016/j.cytogfr.2011.05.001 en
dc.identifier.volume 22 en
dc.identifier.issued 3 en
dc.identifier.startpage 157 en
dc.identifier.endpage 165 en
dc.identifier.uri http://hdl.handle.net/10468/759
dc.identifier.doi 10.1016/j.cytogfr.2011.05.001
dc.description.abstract Parkinson's disease (PD) is a common neurodegenerative disorder caused by the progressive degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine neurotransmission is responsible for the symptoms of the disease. Available treatments are initially successful in treating PD symptoms; however, their long-term use is associated with complications and they cannot stop the neurodegeneration. Current research aims at developing new therapies to halt/reverse the neurodegenerative process, rather than treating symptoms. Neurotrophic factors are proteins critical for maintenance and protection of neurones in the developing and adult brain. Several neurotrophic factors have been investigated for their protective effects on dopaminergic neurones. Here we review some of the most promising factors and provide an update on their status in clinical trials. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.rights Copyright © 2011, Elsevier. NOTICE: this is the author’s version of a work that was accepted for publication in Cytokine & Growth Factor Reviews. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cytokine & Growth Factor Reviews, [22, June 2011] http://dx.doi.org/10.1016/j.cytogfr.2011.05.001 en
dc.subject Glial cell line-derived neurotrophic factor en
dc.subject Growth/differentiation factor 5 en
dc.subject Neurturin en
dc.subject Mesencephalic astrocyte-derived neurotrophic factor en
dc.subject Cerebral dopaminergic neurotrophic factor en
dc.title Neurotrophic factors for the treatment of Parkinson's disease en
dc.type Article (peer-reviewed) en
dc.internal.authorurl http://publish.ucc.ie/researchprofiles/C003/atoulouse en
dc.internal.authorcontactother André Toulouse, Department Of Anatomy & Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: a.toulouse@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2012-11-06T14:07:21Z
dc.description.version Submitted Version en
dc.internal.rssid 92334129
dc.description.status Peer reviewed en
dc.identifier.journaltitle Cytokine & Growth Factor Reviews en
dc.internal.copyrightchecked No. CORA- Checked Romeo and journal publishers website en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress a.toulouse@ucc.ie en


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement